Literature DB >> 28669202

A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.

Samuel T Wilkinson1, Mesut Toprak1, Mason S Turner1, Steven P Levine1, Rachel B Katz1, Gerard Sanacora1.   

Abstract

Entities:  

Keywords:  Epidemiology; Ketamine; Mood Disorders-Bipolar; Mood Disorders-Unipolar

Mesh：

Substances：

Year:  2017        PMID： 28669202      PMCID： PMC5549850          DOI： 10.1176/appi.ajp.2017.17020239

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders.

Authors:  G Sanacora; H Heimer; D Hartman; S J Mathew; M Frye; C Nemeroff; R Robinson Beale
Journal:  Neuropsychopharmacology       Date:  2016-09-19       Impact factor: 7.853

Review 2.  A REVIEW OF KETAMINE ABUSE AND DIVERSION.

Authors:  Sean Sassano-Higgins; Dave Baron; Grace Juarez; Neevon Esmaili; Mark Gold
Journal:  Depress Anxiety       Date:  2016-06-22       Impact factor: 6.505

Review 3.  Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

Authors:  D Jeffrey Newport; Linda L Carpenter; William M McDonald; James B Potash; Mauricio Tohen; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2015-10       Impact factor: 18.112

Review 4.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.

Authors:  A McGirr; M T Berlim; D J Bond; M P Fleck; L N Yatham; R W Lam
Journal:  Psychol Med       Date:  2014-07-10       Impact factor: 7.723

5.  Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.

Authors:  Celia J A Morgan; Leslie Muetzelfeldt; H Valerie Curran
Journal:  Addiction       Date:  2009-11-17       Impact factor: 6.526
  5 in total
  31 in total

1.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.

Authors:  Kai Zhang; Hidetoh Toki; Yuko Fujita; Min Ma; Lijia Chang; Youge Qu; Shingo Harada; Tetsuhiro Nemoto; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2018-09-13       Impact factor: 4.530

2.  Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.

Authors:  Samuel T Wilkinson; Gerard Sanacora
Journal:  JAMA       Date:  2017-09-05       Impact factor: 56.272

3.  Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.

Authors:  Samuel T Wilkinson; Rachel B Katz; Mesut Toprak; Ryan Webler; Robert B Ostroff; Gerard Sanacora
Journal:  J Clin Psychiatry       Date:  2018-07-24       Impact factor: 4.384

Review 4.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 5.  Ketamine: A Paradigm Shift for Depression Research and Treatment.

Authors:  John H Krystal; Chadi G Abdallah; Gerard Sanacora; Dennis S Charney; Ronald S Duman
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

6.  A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.

Authors:  Samuel T Wilkinson; Gerard Sanacora
Journal:  Drug Discov Today       Date:  2018-11-14       Impact factor: 7.851

Review 7.  Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.

Authors:  Samuel T Wilkinson; Paul E Holtzheimer; Shan Gao; David S Kirwin; Rebecca B Price
Journal:  Biol Psychiatry       Date:  2018-09-20       Impact factor: 13.382

8.  Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.

Authors:  Elia E Acevedo-Diaz; Grace W Cavanaugh; Dede Greenstein; Christoph Kraus; Bashkim Kadriu; Lawrence Park; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2020-07-30       Impact factor: 4.791

9.  Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Authors:  Manish K Jha; Madhukar H Trivedi
Journal:  Focus (Am Psychiatr Publ)       Date:  2018-07-18

10.  Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Authors:  Naji C Salloum; Maurizio Fava; Rebecca S Hock; Marlene P Freeman; Martina Flynn; Bettina Hoeppner; Cristina Cusin; Dan V Iosifescu; Madhukar H Trivedi; Gerard Sanacora; Sanjay J Mathew; Charles Debattista; Dawn F Ionescu; George I Papakostas
Journal:  J Affect Disord       Date:  2019-09-03       Impact factor: 4.839
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.